Position in ARVN
as of Jun 30, 2026
· filed Aug 21, 2026
Position Value
$568,869
+$264,268 QoQ
Shares Held
68,456
+138.2% QoQ
Ownership
0.105%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#74
of 198 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Assenagon Asset Management S.A. holds $1,940,218,245 across 69 Biotechnology names. ARVN ranks #55 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
759,564 | $377,298,225 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
8,362,952 | $295,964,871 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
244,927 | $152,721,781 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
454,682 | $111,292,513 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
1,762,086 | $100,826,560 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
997,643 | $78,085,517 | |
| 7 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
124,214 | $66,696,707 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
947,495 | $59,635,335 |
All Filings in ARVN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $568,869 | 68,456 | Shares | Sole | 2026-08-21 | |
| 2026-03-31 | $304,601 | 28,736 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $363,556 | 30,654 | Shares | Sole | 2026-01-09 | |
| 2025-09-30 | $335,645 | 39,395 | Shares | Sole | 2025-10-07 | |
| 2025-06-30 | $370,693 | 50,366 | Shares | Sole | 2025-07-11 | |
| 2025-03-31 | $581,810 | 82,879 | Shares | Sole | 2025-04-15 | |
| 2024-12-31 | $2,693,730 | 140,518 | Shares | Sole | 2025-01-14 | |
| 2024-09-30 | $3,441,820 | 139,741 | Shares | Sole | 2024-10-23 | |
| No filing history on record for this holder in this stock. | ||||||